Teva Pharmaceutical Issues $2.2 Billion in Senior Notes

Summary

On May 28, 2025, Teva Pharmaceutical Industries Limited issued €1 billion in 4.125% Senior Notes due 2031, $500 million in 6.000% Senior Notes due 2032, and $700 million in 5.750% Senior Notes due 2030. The proceeds will be used to fund a tender offer, pay fees and expenses related to the offer, and repay outstanding debt. The notes are senior unsecured obligations of Teva's subsidiaries and guaranteed by the Company.